Cambridge Healthtech Institute’s 3rd Annual

CNS Targets and Translational Strategies

Advancing CNS Drug Development

June 18-19 2019

A greater understanding of CNS related disease biology and the emergence of new, improved targets and technologies is bringing renewed interest, excitement and investment into this transformative area of medicine.

Cambridge Healthtech Institute’s CNS Targets and Translational Strategies conference focuses on the key issues of CNS drug development – including CNS target discovery and validation, biomarkers, bridging the preclinical/ clinical translation gap, evaluating the strengths and weaknesses of current preclinical models, challenging “gold-standards”, understanding mechanism of action, dose selection, neuroimaging, neuroinflamation, neuroimmunology, and more. 2019’s meeting will focus on progress being made in the field of CNS drug development rather than historical reflection.


Targeting KCC2 for Epilepsy and Other Brain Disorders
Nick Brandon PhD, Chief Scientist, Neuroscience, IMED, AstraZeneca

Lysosomal Dysfunction in Parkinson's Disease: From Genetics to the Clinic
Pablo Sardi, PharmD, PhD, R&D Director, Sanofi

New Targets and Biology in Neuroimmunology
Samuel Hasson, PhD, Senior Scientist, Neuroscience, Amgen

Targeting Nucleocytoplasmic Transport in Amyotrophic Lateral Sclerosis and Dementia
Fernande Freyermuth, PhD, Massachusetts General Hospital, Mass General Institute for Neurodegenerative Diseases

Zebrafish Models for Early Research and Development in Neurodegenerative and Neuromuscular Diseases
Arantza Muriana, Co-Founder & CEO, Biobide USA 



Translational Strategies to Optimize Drug Development for Neurodegenerative Disorders
Holly D. Soares, PhD, Head, Translational Neuroscience, Abbvie

Translatability of Early Development Proof of Principle Trials in Neurology
Johan Luthman, PhD, Vice President, Neuroscience Clinical Development, Neurology Business Group, Eisai, Inc.

Preclinical Translational Strategies for the Neuroinflammatory Aspects of Neurodegenerative Disease
Jonathan Levenson, PhD, Vice President, Translational Biology, Tiaki Therapeutics

Behavior & Biomarker Characterization of the SOD1G93A Model of ALS following Chronic Dosing with a Brain Penetrant HDAC6 Inhibitor Compound
Shahriar Niroomand, PhD, Senior Scientist, Neuroscience, Merck Research Laboratories

Talk Title to be Announced
David H. Donabedian, PhD, Co-Founder & CEO, Axial Biotherapeutics

Novel Markers that Significantly Enhance the Prediction of Alexandra’s Disease Progression
Viswanath Devanarayan, PhD, Adjunct Professor, University of Illinois, Chicago

The TSC Preclinical Consortium: De-Risking Drug Discovery and Repurposing for Tuberous Sclerosis ComplexSteven Roberds, PhD, CSO, Tuberous Sclerosis Alliance

For more details on the conference, please contact:
Daniel Barry
Senior Conference Director
Cambridge Healthtech Institute
Phone: (+44) 783-765-1303

For partnering and sponsorship information, please contact:

Companies A-K
Rod Eymael
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-247-6286

Companies L-Z
Joseph Vacca, M.S.
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5431